Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Acupuncture vs other active therapy Participant‐reported pain intensity · adults with neuropathic pain Acupuncture for neuropathic pain in adults (2017) · Cochrane | no estimate extracted | NR | No studies |
Desmopressin vs placebo Time to first void ‐ not reported Desmopressin for treating nocturia in men (2017) · Cochrane | no estimate extracted | NR | No studies |
Desmopressin vs behaviour modifications Number of nocturnal voids ‐ not reported Desmopressin for treating nocturia in men (2017) · Cochrane | no estimate extracted | NR | No studies |
Desmopressin vs behaviour modifications Quality of life ‐ not reported Desmopressin for treating nocturia in men (2017) · Cochrane | no estimate extracted | NR | No studies |
Desmopressin vs behaviour modifications Major adverse events ‐ not reported Desmopressin for treating nocturia in men (2017) · Cochrane | no estimate extracted | NR | No studies |
Desmopressin vs behaviour modifications Time to first void ‐ not reported Desmopressin for treating nocturia in men (2017) · Cochrane | no estimate extracted | NR | No studies |
Desmopressin vs placebo Quality of life ‐ not reported Desmopressin for treating nocturia in men (2017) · Cochrane | no estimate extracted | NR | No studies |
Desmopressin vs behaviour modifications Minor adverse events ‐ not reported Desmopressin for treating nocturia in men (2017) · Cochrane | no estimate extracted | NR | No studies |
Desmopressin vs behaviour modifications Treatment withdrawal due to adverse event ‐ not reported Desmopressin for treating nocturia in men (2017) · Cochrane | no estimate extracted | NR | No studies |
Desmopressin vs alpha‐blocker Duration of first sleep episode ‐ not reported Desmopressin for treating nocturia in men (2017) · Cochrane | no estimate extracted | NR | No studies |
Desmopressin vs alpha‐blocker Time to first void ‐ not reported Desmopressin for treating nocturia in men (2017) · Cochrane | no estimate extracted | NR | No studies |
Desmopressin plus alpha‐blocker vs alpha‐blocker Duration of first sleep episode ‐ not reported Desmopressin for treating nocturia in men (2017) · Cochrane | no estimate extracted | NR | No studies |
Desmopressin plus alpha‐blocker vs alpha‐blocker Time to first void ‐ not reported Desmopressin for treating nocturia in men (2017) · Cochrane | no estimate extracted | NR | No studies |
Desmopressin plus alpha‐blocker vs alpha‐blocker plus anticholinergic Quality of life ‐ not reported Desmopressin for treating nocturia in men (2017) · Cochrane | no estimate extracted | NR | No studies |
Desmopressin plus alpha‐blocker vs alpha‐blocker plus anticholinergic Duration of first sleep episode ‐ not reported Desmopressin for treating nocturia in men (2017) · Cochrane | no estimate extracted | NR | No studies |
Desmopressin plus alpha‐blocker vs alpha‐blocker plus anticholinergic Time to first void ‐ not reported Desmopressin for treating nocturia in men (2017) · Cochrane | no estimate extracted | NR | No studies |
Desmopressin vs placebo Quality of life ‐ not reported Desmopressin for treating nocturia in men (2017) · Cochrane | no estimate extracted | NR | No studies |
Beta‐2 agonists vs placebo Participant‐reported outcomes: quality of life (measured by CFQ‐R) · adults and children with cystic fibrosis Long‐acting inhaled bronchodilators for cystic fibrosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Beta‐2 agonists vs placebo Adverse events after tiotropium 5.0 µg · adults and children with cystic fibrosis Long‐acting inhaled bronchodilators for cystic fibrosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Beta‐2 agonists vs placebo Pulmonary exacerbations · adults and children with cystic fibrosis Long‐acting inhaled bronchodilators for cystic fibrosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Beta‐2 agonists vs placebo Other measures of lung function · adults and children with cystic fibrosis Long‐acting inhaled bronchodilators for cystic fibrosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Intravesically administered BCG alternating with IFN‐α vs intravesically administered BCG alone Disease‐specific quality of life ‐ not measured · patients with non‐muscle invasive bladder cancer Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intravesically administered BCG combined with IFN‐α vs intravesically administered BCG alone Discontinuation of therapy due to adverse events ‐ not measured · patients with non‐muscle invasive bladder cancer Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intravesically administered BCG combined with IFN‐α vs intravesically administered BCG alone Disease‐specific quality of life ‐ not measured · patients with non‐muscle invasive bladder cancer Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for… (2017) · Cochrane | no estimate extracted | NR | No studies |
Moisturisers vs no treatment (no moisturiser) Change from baseline in disease severity according to participants ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Atopiclair vs vehicle Change in use of topical active treatment ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Atopiclair vs vehicle Change from baseline in health‐related quality of life ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Moisturisers vs no treatment (no moisturiser) Participant satisfaction ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Urea‐containing moisturisers vs vehicle, placebo or no moisturiser Change in use of topical active treatment ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Urea‐containing moisturisers vs vehicle, placebo or no moisturiser Change from baseline in health‐related quality of life ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Glycerin/glycerol‐containing moisturisers vs vehicle or placebo Participant satisfaction ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Glycerin/glycerol‐containing moisturisers vs vehicle or placebo Number of participants who experienced a flare ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Glycerin/glycerol‐containing moisturisers vs vehicle or placebo Change in use of topical active treatment ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Glycerin/glycerol‐containing moisturisers vs vehicle or placebo Change from baseline in health‐related quality of life ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Licochalcone‐containing moisturiser vs hydrocortisone acetate 1% cream Change from baseline in disease severity according to participants ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Licochalcone‐containing moisturiser vs hydrocortisone acetate 1% cream Change in use of active topical treatment ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Licochalcone‐containing moisturiser vs hydrocortisone acetate 1% cream Change from baseline in quality of life ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Vehicle treatment + daily moisturiser vs fluticasone propionate twice weekly + daily moisturiser Participant satisfaction ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Vehicle treatment + daily moisturiser vs fluticasone propionate twice weekly + daily moisturiser Change in use of topical active treatment ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Vehicle treatment + daily moisturiser vs fluticasone propionate twice weekly + daily moisturiser Change from baseline in quality of life ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Topical active treatment in combination with moisturiser vs topical active treatment alone Change from baseline in disease severity according to participants ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Topical active treatment in combination with moisturiser vs topical active treatment alone Change in amount of use topical active treatment ‐ not measured · people with eczema Emollients and moisturisers for eczema (2017) · Cochrane | no estimate extracted | NR | No studies |
Yoga package vs standard care Mental State: clinically important change · patients with schizophrenia Yoga as part of a package of care versus standard care for schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
Yoga package vs standard care Social functioning: clinically important change · patients with schizophrenia Yoga as part of a package of care versus standard care for schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
Yoga package vs standard care Adverse events: clinically important adverse effect · patients with schizophrenia Yoga as part of a package of care versus standard care for schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
Yoga package vs standard care Costs of care: direct and indirect · patients with schizophrenia Yoga as part of a package of care versus standard care for schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
Yoga package vs standard care Physical health: clinically important change · patients with schizophrenia Yoga as part of a package of care versus standard care for schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
Airway bypass stents vs control Cost effectiveness · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Intrabronchial valves vs control Cost‐ effectiveness · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | NR | No studies |
AeriSeal vs control Change from baseline in lung function parameters other than FEV1 · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | NR | No studies |